Bio-Path Holdings Inc (BPTH) was Reiterated by Maxim Group to “Buy” while Lowering the Price Target of the company shares to $ 2 from a previous price target of $5 . Maxim Group advised their investors in a research report released on Aug 10, 2016.
Bio-Path Holdings Inc closed down -0.02 points or -1.15% at $1.72 with 1,98,879 shares getting traded on Monday. Post opening the session at $1.74, the shares hit an intraday low of $1.7 and an intraday high of $1.74 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Jul 15, 2015, Michael J. Garrison (director) purchased 7,343 shares at $1.22 per share price.
Bio-Path Holdings Inc. is a clinical-stage biotechnology company. The Company is focused on developing cancer drugs under a license arrangement. The Company’s lead cancer drug candidate Liposomal Grb-2 (L-Grb-2 or BP1001) is undergoing clinical trials. The Company’s two liposomal antisense drug candidates are focused to treat acute myeloid leukemia (AML) myelodysplastic syndrome (MDS) chronic myelogenous leukemia (CML) acute lymphoblastic leukemia (ALL) and follicular lymphoma. BP1001 is its lead liposome delivered antisense drug candidate which has been clinically tested in patients having AML CML MDS and ALL. BP-100-1.02 (Bcl-2 or BP1002) is its second liposome delivered antisense drug candidate. Clinical targets for BP1002 include lymphoma breast cancer colon cancer prostate cancer and leukemia. The Company has a drug delivery platform technology with composition of matter intellectual property for systemic delivery of antisense.